Safety and Efficacy of Melperone in the Treatment of Patients with Psychosis Associated with Parkinson's Disease.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-000307-15-IT

Enrollment

Registered

2007-08-23

Start date

2007-04-24

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psicosi associata al morbo di Parkinson MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's

Interventions

Product Name: Melperon Pharmaceutical Form: Syrup INN or Proposed INN: melperon Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Pharmaceutical form

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: The primary objective is to assess the safety and efficacy of 20, 40, and 60 mg per day of melperone syrup (5 mg/ml) in subjects with psychosis associated to Parkinson’s Disease. ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026